What is the core difference between tirzepatide and semaglutide?
The most fundamental distinction is receptor targeting. Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. It selectively activates the glucagon-like peptide-1 receptor, which is expressed in the pancreas, the gut, and the brain’s hypothalamus and brainstem regions involved in appetite regulation.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is an incretin hormone produced by the small intestine. In addition to its role in insulin secretion, GIP receptors in adipose tissue and the central nervous system appear to influence energy homeostasis through pathways that complement GLP-1 signaling.
This dual-receptor mechanism is not just a marketing distinction. It represents a different pharmacological approach, and the clinical trial data suggests the combination produces a meaningfully different efficacy and tolerability profile than GLP-1 agonism alone.
How GLP-1 and GIP work together
Understanding why dual agonism matters requires a brief look at what each receptor does when activated.
GLP-1 receptor activation
GLP-1 is released by intestinal L-cells after eating. GLP-1 receptor activation produces:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon (which would otherwise raise blood sugar)
- Slowed gastric emptying, which extends post-meal satiety
- Central appetite modulation through hypothalamic and brainstem receptors, reducing food intake
GIP receptor activation
GIP is the other major incretin hormone. Its receptor is expressed in the pancreas, adipose tissue, bone, and the central nervous system. GIP receptor activation contributes to:
- Glucose-dependent insulin secretion (similar to GLP-1)
- Potentially improved tolerability: GIP receptor co-agonism may reduce nausea and gastrointestinal side effects associated with GLP-1 agonism alone, though the mechanism is not fully characterized
- Central appetite and energy expenditure effects via hypothalamic GIP receptors, though this is still an active area of research
The combination appears to produce additive or synergistic effects on weight reduction in clinical trials, with a tolerability profile that some patients find more manageable than high-dose GLP-1 agonism alone.
What does the clinical trial data show?
Several landmark randomized controlled trials have assessed both tirzepatide and semaglutide in the context of weight management. Note that all trial data referenced here was generated using FDA-approved brand products in controlled research settings—not compounded formulations.
The STEP 1 trial of once-weekly semaglutide 2.4 mg demonstrated a mean weight reduction of approximately 14.9% of body weight over 68 weeks in adults with obesity or overweight without diabetes.
The SURMOUNT-1 trial of once-weekly tirzepatide 15 mg demonstrated mean weight reductions ranging from approximately 15% to 20.9% of body weight over 72 weeks in a similar population.
The SURPASS-2 head-to-head trial, conducted in patients with type 2 diabetes, found that tirzepatide outperformed semaglutide 1 mg on glycemic control and body weight at all doses tested.
These data points explain why tirzepatide is often described as the more potent option. However, individual response varies substantially, and “more potent on average” does not predict outcomes for any specific person. Tolerability, adherence, and co-existing health factors all influence which molecule is more appropriate for a given patient.
Tirzepatide hits two incretin receptors where semaglutide hits one — a different molecule, not a stronger version of the same drug.
Ozempic, Wegovy, Mounjaro, Zepbound — what is each brand?
The brand name landscape adds to the confusion. Here is what each product actually is:
| Brand | Active ingredient | FDA approval | Receptor target |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | GLP-1 |
| Wegovy | Semaglutide (2.4 mg) | Chronic weight management | GLP-1 |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | GLP-1 |
| Mounjaro | Tirzepatide | Type 2 diabetes | GIP + GLP-1 |
| Zepbound | Tirzepatide | Chronic weight management | GIP + GLP-1 |
Compounded semaglutide and compounded tirzepatide are neither of these products. They are prepared by licensed 503A compounding pharmacies for individual patients with a valid prescription. They are not FDA-approved, and they are not the same as the branded products listed above, either in terms of regulatory status or chemical form.
Which compounded versions are legally available?
Both semaglutide and tirzepatide have been available through licensed 503A compounding pharmacies in the United States during periods when the FDA has recognized shortage conditions for the branded products. The regulatory landscape around compounding exemptions for these molecules is subject to change as shortage designations are updated.
If you are evaluating compounded GLP-1 therapy, the legally sound pathway is:
- A licensed clinician evaluates you and determines whether a GLP-1 receptor agonist protocol is appropriate.
- The clinician selects the molecule (semaglutide or tirzepatide) and writes a prescription.
- The prescription is filled by a licensed US 503A compounding pharmacy using pharmaceutical-grade ingredients.
PepScribe partners exclusively with licensed US 503A pharmacies. No hidden overseas supply chain. No unregulated sourcing.
Frequently asked questions
Is tirzepatide the same as Ozempic?
No. Tirzepatide and Ozempic (semaglutide) are different molecules with different mechanisms. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GIP and GLP-1 receptors. They share some pharmacological overlap but are structurally and mechanistically distinct.
What is Ozempic?
Ozempic is a brand name for injectable semaglutide, an FDA-approved GLP-1 receptor agonist originally approved for type 2 diabetes management. Wegovy is semaglutide at a higher dose approved for chronic weight management. Compounded semaglutide is a different preparation — not FDA-approved and not the same as Ozempic or Wegovy.
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Mounjaro (for diabetes) and Zepbound (for weight management) are FDA-approved tirzepatide brand products. Compounded tirzepatide is not FDA-approved.
Which is stronger, tirzepatide or semaglutide?
Head-to-head clinical comparisons suggest tirzepatide produces greater average weight reduction in clinical trials, but outcomes vary substantially by individual. "Stronger" is a simplification — which is more appropriate depends on your physiology, tolerability, and clinician assessment.
Can I get compounded tirzepatide or semaglutide without a prescription?
No. Both compounded semaglutide and compounded tirzepatide require a valid prescription from a licensed clinician. They must be dispensed by a licensed 503A compounding pharmacy. Purchasing from unregulated online sources carries serious safety risks.
Are compounded versions of tirzepatide or semaglutide FDA-approved?
No. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. They are prepared by licensed 503A pharmacies under applicable compounding law for individual patients with a valid prescription.